Earnings · China A-shares
Chengdu Easton Biopharmaceuticals Co., Ltd. Class A (688513) earnings
Chengdu Easton Biopharmaceuticals Co., Ltd. Class A published its Q3 report on 2026-10-27: net profit -5.24% year on year, -4.56% excluding one-off items. Wave Radar's earnings-quality score is 100 of 100 (Sound). The stock moved +0.61% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-27
- Period end
- 2026-09-30
- Net profit YoY
- -5.24%
- Excl. one-offs YoY
- -4.56%
- Net profit QoQ
- -0.07%
- Result
- Neutral
- Quality score
- 100
- Quality
- Sound
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | +2.72% | — |
| 3 days | +0.61% | — |
| 7 days | +3.85% | — |
| 14 days | +2.79% | — |
Report history
Over the last 8 reports, net profit grew year on year in 3 of them. The stock rose in the 3 trading days after 3 of 6 reports (average -3.68%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-28 | ¥208.62M | -5.24% | -4.56% | -2.81% | 1.20 | 6.97% | +0.61% | — | — |
| 2026 interim report | 2026-08-21 | ¥129.75M | -4.99% | -9.75% | +0.68% | 0.74 | 4.33% | -8.48% | -3.97% | +1.73% |
| 2026 Q1 report | 2026-04-22 | ¥50.83M | -16.11% | -17.81% | +6.75% | 0.29 | 1.72% | -3.10% | -28.47% | -30.06% |
| 2025 annual report | 2026-04-22 | ¥284.06M | +19.24% | +19.02% | -1.36% | 1.63 | 10.10% | -3.10% | -28.47% | -30.06% |
| 2025 Q3 report | 2025-10-28 | ¥220.16M | +1.45% | +3.10% | -2.00% | 1.25 | 7.93% | +1.74% | +4.69% | +8.07% |
| 2025 interim report | 2025-08-19 | ¥136.57M | -6.77% | -8.68% | -2.25% | 0.77 | 4.97% | +1.21% | -14.80% | -23.97% |
| 2025 Q1 report | 2025-04-25 | ¥60.59M | -19.22% | -10.79% | -2.97% | 0.34 | 2.22% | -14.04% | +13.11% | +9.87% |
| 2024 annual report | 2025-04-25 | ¥238.23M | +5.15% | +10.90% | +20.82% | 1.36 | 9.14% | -14.04% | +13.11% | +9.87% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.